Last reviewed · How we verify
Sanfujiu
Sanfujiu is a Small molecule drug developed by Guangdong Provincial Hospital of Traditional Chinese Medicine. It is currently in Phase 3 development. Also known as: Sanfu-moxibustion.
Sanfujiu is an herbal plaster used in the treatment of allergic rhinitis, as studied in clinical trials. It has been investigated alongside acupuncture in the treatment of allergic rhinitis, with one study (NCT02486159) analyzing its effects using oligonucleotide chip analysis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sanfujiu |
|---|---|
| Also known as | Sanfu-moxibustion |
| Sponsor | Guangdong Provincial Hospital of Traditional Chinese Medicine |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Sanfujiu on Patients With Persistent Allergic Rhinitis: Randomized Controlled Study (PHASE3)
- The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sanfujiu CI brief — competitive landscape report
- Sanfujiu updates RSS · CI watch RSS
- Guangdong Provincial Hospital of Traditional Chinese Medicine portfolio CI
Frequently asked questions about Sanfujiu
What is Sanfujiu?
Who makes Sanfujiu?
Is Sanfujiu also known as anything else?
What development phase is Sanfujiu in?
Related
- Manufacturer: Guangdong Provincial Hospital of Traditional Chinese Medicine — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Sanfu-moxibustion
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing